This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elliott, T. B. Articles by Knudson, G. B. Search for Related Content PubMed PubMed Citation Articles by Elliott, T. B. Articles by Knudson, G. B.

Antimicrobial Therapy for Bacillus anthracis-Induced Polymicrobial Infection in ⁶⁰Co -Irradiated Mice

Thomas B. Elliott,^* Itzhak Brook, Rita A. Harding, S. Samy Bouhaouala, Michael O. Shoemaker, and Gregory B. Knudson

Nuclear, Biological, and Chemical Interactions and Countermeasures Research Team, Radiation Medicine Department, Armed Forces Radiobiology Research Institute, Bethesda, Maryland 20889-5603

Received 20 May 2002/ Accepted 15 July 2002

Challenge with both nonlethal ionizing radiation and toxigenic Bacillus anthracis spores increases the rate of mortality from a mixed bacterial infection. If biological weapons, such as B. anthracis spores, and nuclear weapons were used together, casualties could be more severe than they would be from the use of either weapon alone. We previously discovered that a polymicrobial infection developed in B6D2F₁/J mice after nonlethal (7-Gy) ⁶⁰Co irradiation and intratracheal challenge with B. anthracis Sterne spores 4 days after irradiation. In this present study, we investigated the survival of mice and the response of the polymicrobial infection during the course of antimicrobial therapy with penicillin G procaine, ofloxacin, trovafloxacin, or gatifloxacin. Survival was prolonged, but not ensured, when the mice were treated with either broad-spectrum ofloxacin or narrow-spectrum penicillin G for 7 days beginning 6 or 24 h after challenge. Survival was not prolonged when therapy was delayed more than 24 h after challenge. When these two antimicrobial agents were given for 21 days, the survival rate was increased from 0% for the controls to 38 to 63% after therapy. Therapy with trovafloxacin or gatifloxacin reduced the incidence of mixed infection and improved the rate of survival to 95% (trovafloxacin) or 79% (gatifloxacin), whereas the rate of survival for the controls was 5%. We conclude that the mixed infection induced by B. anthracis in irradiated mice complicates effective therapy with a single antimicrobial agent. To limit mortality following nonlethal irradiation and challenge with B. anthracis spores, antimicrobial therapy needs to be initiated within a few hours after challenge and continued for up to 21 days.

Present address: Center for Bioresource Development, George Mason University, Manassas, VA 20110.

This article has been cited by other articles:

• Heine, H. S., Bassett, J., Miller, L., Hartings, J. M., Ivins, B. E., Pitt, M. L., Fritz, D., Norris, S. L., Byrne, W. R. (2007). Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model. Antimicrob. Agents Chemother. 51: 1373-1379 [Abstract] [Full Text]  
• Brook, I., Germana, A., Giraldo, D. E., Camp-Hyde, T. D., Bolduc, D. L., Foriska, M. A., Elliott, T. B., Thakar, J. H., Shoemaker, M. O., Jackson, W. E., Ledney, G. D. (2005). Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. J Antimicrob Chemother 56: 1074-1080 [Abstract] [Full Text]  
• Brook, I., Giraldo, D. E, Germana, A., Nicolau, D. P, Jackson, W. E, Elliott, T. B, Thakar, J. H, Shoemaker, M. O, Ledney, G D. (2005). Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without 60Co gamma-photon irradiation. J Med Microbiol 54: 1157-1162 [Abstract] [Full Text]  
• Steward, J., Lever, M. S., Simpson, A. J. H., Sefton, A. M., Brooks, T. J. G. (2004). Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J Antimicrob Chemother 54: 95-99 [Abstract] [Full Text]